COVID-19 Key Visual 16-9

Siemens Healthineers at the PAMET 25th Midyear ConventionMay 19 – 21, 2021 | PAMET Mid Year Convention

Siemens Healthineers | PAMET 25TH Midyear Convention | May 19-21, 2021


The Philippine Association of Medical Technologists, Inc. (PAMET) holds its 25th Midyear Convention with the theme "PAMET Into the Future: Silver Lining, Golden Opportunities."

Siemens Healthineers showcases its latest innovation in the field of laboratory diagnostics and point-of-care for urinalysis such as Atellica® 1500, a digital automated urinalysis system. Furthermore, discover more about our comprehensive COVID-19 Testing portfolio and its position in the setting of vaccination - highlighting SARS-CoV-2 Serology Testing as we move into the next phase of the pandemic.

At Siemens Healthineers, we continue to support healthcare providers and enabling healthcare systems to provide the best possible care for patients.

Date: 19 to 21 May 2021
Venue: PAMET Mid-year Virtual Showroom 

Dr. Jecyll Dayanghirang

As we start rolling out COVID-19 vaccination programs, we invite you to join our clinical presentation on "How can Covid-19 serology testing support vaccine rollout?" at the PAMET 25th Midyear Convention. 

Speaker: Dr. Jecyll S. Dayanghirang, Marketing Manager for Diagnostics Siemens Healthineers Philippines
When: May 20, 2021 | 5:15 PM Philippine Standard Time


A urinalysis system so advanced, it lets you do less and see more. Combining the CLINITEK Novus® Analyzer and the new Atellica® UAS 800 Analyzer* into one completely automated unit, the Atellica 1500 Automated Urinalysis System* sets the new standard for accuracy and efficiency. It is a truly digital automated urinalysis system, and lets you manage more samples with less staff in shorter time, while never compromising on high-quality results.

The system

The Analyzers

CLINITEK Novus® Automated Urine Chemistry Analyzer

The Analyzers
Atellica® UAS 800 Urine Sediment Analyzer

Do Less and See More

SARS-CoV-2 antibody test from Siemens Healthineers evaluated against other leading antibody assays in Public Health England study distinguishing itself as the only assay tested found to meet both the sensitivity and specificity requirements set out within the MHRA’s Target Product Profile for immunoassays.

We are committed to support front-line healthcare professionals and help them to deliver high-value critical care to patients at each stage of COVID-19 disease management: diagnosis, prognosis, therapy and follow-up.